
Business Development: Identifying R&D Opportunities for Strategic Growth

Jessica Droge, PhD


What is Strategic Growth?



The Process of Evaluating Opportunities



Identifying and Assessing Opportunities





Considerations when Identifying and Assessing Opportunities

- Indication
- Target / Mechanism of Action
- Modality
 - protein/peptide, antibody, small molecule, etc
- Clinical Development Plan
- Manufacturing
- Intellectual Property
- Commercialization



What is the Indication?

- Is there an unmet need?
- What is the potential patient population?
- Are there ways to improve upon current treatments?
- Are there good preclinical models?
- Is it a fit within the organization?



Mechanism of Action and Modality

- Is it novel?
- Existing research and studies?
- Protein / peptide?
- Antibody?
- Small molecule?
- These have important efficacy and safety implications
 - Downstream pathway effects
 - Toxicology profile and off target effects
 - Immunogenicity
- Dosing and administration implications



Development Plan and Manufacturing

- Development Plan
 - Is there a known regulatory path?
 - What effect size is anticipated?
 - What risks are anticipated and can they be mitigated?
 - Is it feasible to design an appropriate study?
 - How long and big will the clinical trials need to be?

- Manufacturing
 - What is the "cost of goods"?
 - Formulation issues
 - Storage and Stability



Intellectual Property and Commercialization

- Intellectual Property
 - Does it have protection?
- Commercialization
 - Will this be first to market?
 - Best-in-class?
 - How long before generics / biosimilars can enter the market?
 - Is there a current sales force?
 - Will it be acceptable to payers?



Identifying and Assessing Opportunities Requires Experience and Collaboration

- Chemistry / Protein Sciences
- Protein Sciences
- Research
- Toxicology
- PKPD
- Clinical Development
- Regulatory
- Safety
- Manufacturing
- Legal
- Commercial



Thank you

